Synthesis and Characterization of Aroylhydrazino Derivatives of Pharmacologically Active Pyrimidine-5-carbonitrile

Thanki Pragna, Hingrajia Dhaval, Modha Jayesh*
Department of Chemistry, Maharshi Dayanand Science College, Porbandar, Gujarat, India
*E-mail address: drjmodha@gmail.com

ABSTRACT

The target compound N’-(5-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)-4-methylbenzohydrazide have been synthesized by the condensation of 4-(4-Fluorophenyl)-2-hydrazinyl-1,6-dihydro-1-methyl-6-oxopyrimidine-5-carbonitrile with different aroylchlorides. The obtained products were characterized by 1H NMR, Mass and IR Spectra.

Keyword: Pyrimidine-5-carbonitrile; Aroylchlorides; Benzohydrazide

1. INTRODUCTION

A massive number of Heterocyclic compounds are known and are increasing rapidly. The literature on the subject is very wide. Heterocyclic systems are found in variety of naturally occurring and synthetic compounds and are essential to life. They are important components of alkaloids, antibiotics, hormones and large number of synthetic drugs and dyes [1]. The Nitrogen Heterocyclics are of great importance as they are present in nucleic acids, vitamins, proteins and other biologically important molecular systems [2].

Amide functional group is found widely in small or complex synthetic as well as natural molecules. It is ubiquitous in life as proteins play a crucial role in virtually all biological processes such as enzymatic catalysis (nearly all known enzymes are proteins), transport/storage (haemoglobin), immune protection (antibodies) and mechanical support (collagen). Amides also play a key role for medicinal chemists [3]. An in-depth analysis of the Comprehensive Medicinal Chemistry database revealed that the carboxamide group appears in more than 25 % of known drugs [4]. This can be expected, since carboxamides are neutral, stable and have both hydrogen-bond accepting and donating properties [5].

The 3,4-Dihydropyrimidine derivatives are known to exhibit traditional antithyroid activity of the 5-Fluoro-2-thiouracil[6]. Furthermore, Dihydropyrimidine derivatives are also reported to have showed different pharmacological activities like antitumor [7], analgesic [8], antineoplastic [9], cardiovascular [10], antiallergic [11] etc.

Many acyclic and cyclic amide derivatives have resulted into powerful central nervous depressant. The biological activity of arylamide derivatives have been reported as antitubercular [12], anticancer [13], antibacterial [14-15], CNS depressant [16-17].
Also Incorporation of Aroylhydrazino group in 3,4-Dihydropyrimidine is reported to have increased the biological activity of Pyrimidine-5-carbonitrile [18].

Going through the references and in search of newer pharmacologically active Pyrimidine-5-carbonitrile derivatives, we have synthesized some new N’-(5-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)-4-methylbenzohydrazide by condensation of 4-(4-Fluorophenyl)-2-hydrazone-1,6-dihydro-1-methyl-6-oxopyrimidine-5-carbonitrile with different Aroylchlorides using 3-component Heterocyclization method[19]. Compound (1) and (2) have been synthesized by reported method [20].

2. EXPERIMENTAL

Melting points were taken in open capillary and are not corrected. Purity of synthesized compounds have been checked by TLC. Mass spectra were determined on Shimadzu-QP2010 spectrometer. IR spectra were recorded on Shimadzu-FTIR-8400 using KBr pallet. ¹H NMR spectra were recorded in Bruker-Avance-II( 400 MHz) using DMSO-d6 as a solvent and TMS as an internal standard and the chemical shifts are reported as parts per million (ppm).

![Scheme 1](image.png)

2.1 Synthesis of 6-(4-Fluorophenyl)-1,2,3,4-tetrahydro-4-oxo-2-thioxopyrimidine-5-carbonitrile (1)

A mixture of Thiourea (0.05 mol), ethylcyanoacetate (0.05 mol), 4-Fluorobenzaldehyde (0.05 mol) and potassium carbonate (0.05mol) in absolute alcohol (100 ml) was refluxed for 6 hours. Reaction mixture was poured into minimum quantity of crushed ice and neutralized with acetic acid. The product obtained was isolated and crystallized from absolute alcohol.
Mass $M^+ = 247$: IR (KBr) v (cm$^{-1}$), 2943 (-CH$_3$, Asym.), 2855 (-CH$_3$, Sym.), 2208 (-CN), 1635 (-CO), 1245 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 7.2-7.3 (t, 2H, Ar-H), δ 7.7-7.8 (q, 2H, Ar-H).

2. 2. Synthesis of 4-(4-Fluorophenyl)-1,6-dihydro-1-methyl-2-(methylthio)-6-oxopyrimidine-5-carbonitrile (2)

To a solution of (1) (0.05 mol) in DMF (70 ml), potassium carbonate (0.1 mol) and methyliodide (0.1 mol) were added and the mixture was stirred for 3 hours. The contents were poured into water, filtered, washed with water and crystallized from absolute alcohol. Mass $M^+ = 275$: IR (KBr) v (cm$^{-1}$), 3304 (-NH, secondary) 2954 (-CH$_3$, Asym.), 2868 (-CH$_3$, Sym.), 2216 (-CN), 1670 (-CO), 1250 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 2.6 (s, 3H, S-CH$_3$), δ 3.2 (s, 3H, N-CH$_3$), δ 7.2-7.3 (t, 2H, Ar-H), δ 7.43-7.48 (q, 2H, Ar-H).

2. 3. Synthesis of 4-(4-Fluorophenyl)-2-hydrazinyl-1,6-dihydro-1-methyl-6-oxopyrimidine-5-carbonitrile (3)

A mixture of (2) (0.01 mol) and Hydrazine hydrate (3.5 ml) in absolute alcohol (30 ml) was refluxed for 8 hours. The reaction mixture was poured into crushed ice and the solid product obtained after neutralization with acetic acid was kept in water overnight. The product was isolated and crystallized from absolute alcohol. Mass $M^+ = 259$: IR (KBr) v (cm$^{-1}$), 3304 (-NH, secondary) 2954 (-CH$_3$, Asym.), 2868 (-CH$_3$, Sym.), 2216 (-CN), 1670 (-CO), 1250 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 7.0-7.1 (d, 1H, Ar-H), δ 7.3-7.4 (t, 1H, Ar-H), δ 7.9-8.0 (q, 2H, Ar-H).

2. 4. Synthesis of N'-[(3-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)]benzohydrazide derivatives(4a-j)

A mixture of (3) (0.01 mol) and different aroylchloride (0.01 mol) in chloroform (20 ml) was refluxed for 3 hours in presence of catalytic amount of dry pyridine. The reaction mixture was poured into ice water. The product was isolated and crystalized from appropriate solvent.

3. SPECTRAL ANALYSIS OF NOVEL ARYLAMIDE DERIVATIVES

3. 1. N'-[(3-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)]-4-methylbenzohydrazide (4a):

Mass $M^+ = 377$: IR (KBr) v (cm$^{-1}$), 3432 (-NH, secondary), 2925 (-CH$_3$, Asym.), 2830 (-CH$_3$, Sym.), 2204 (-CN), 1638 (-CO), 1092 (N-C), 1608 (-CO, Amide), 1259 (C-O-C), 1240 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 7.2-7.3 (q, 2H, Ar-H), δ 7.80-7.86 (m, 2H, Ar-H).

3. 2. 2-Chloro-N'-[(3-cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)]-5-nitrobenzohydrazide (4b):

Mass $M^+ = 442$: IR (KBr) v (cm$^{-1}$), 3430 (-NH, secondary), 2922 (-CH$_3$, Asym.), 2828 (-CH$_3$, Sym.), 2200 (-CN), 1635 (-CO), 1090 (N-C), 1610 (-CO, Amide), 1257 (C-O-C), 764 (C-Cl), 1365 (C-NO$_2$), 1270 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 3.41 (s, 3H, N-CH$_3$), δ 8.15 (1H, Ar-H), δ 7.38 (1H, Ar-H).
3. 3. 4-Chloro-N’-(5-cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-y1) benzohydrazide (4c):

Mass M⁺ = 397: IR (KBr) v (cm⁻¹), 3432 (-NH, secondary), 2920 (-CH₃, Asym.), 2830 (-CH₃, Sym.), 2210 (-CN), 1630 (-CO), 1095 (N-C), 1620 (-CO, Amide), 1260 (C-O-C), 760 (C-Cl), 1255 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 3.38 (s, 3H, N-CH₃), δ 7.22-7.28 (q, 2H, Ar-H), δ 7.78-7.80 (m, 2H, Ar-H).

### Table 1. Physical constant.

| Comp. | R     | M.F.               | MP°C | Yield % | % of C Found (Calcd.) | % of H Found (Calcd.) | % of N Found (Calcd.) |
|-------|-------|--------------------|------|---------|-----------------------|-----------------------|-----------------------|
| 1     | -     | C₁₁H₆FN₃OS        | 290  | 60%     | 51.60 (51.65)          | 5.25 (5.30)            | 20.00 (20.08)         |
| 2     | -     | C₁₃H₁₀FN₅O        | 182  | 65%     | 55.34 (55.37)          | 6.30 (6.37)            | 17.65 (17.71)         |
| 3     | -     | C₁₂H₁₀FN₅O        | 240  | 55%     | 54.26 (54.28)          | 6.80 (6.83)            | 31.60 (31.65)         |
| 4a    | -4-CH₃| C₁₆H₁₆FN₅O₂       | 260  | 66%     | 63.70 (63.65)          | 4.21 (4.27)            | 18.50 (18.56)         |
| 4b    | -2-Cl-5-NO₂| C₁₉H₁₂ClFN₆O₄ | 225  | 64%     | 51.46 (51.54)          | 2.70 (2.73)            | 18.90 (18.98)         |
| 4c    | -4-Cl  | C₁₉H₁₃ClFN₅O₂     | 208  | 57%     | 57.30 (57.37)          | 3.25 (3.29)            | 17.54 (17.61)         |
| 4d    | -H    | C₁₀H₁₄FN₅O₂       | 220  | 60%     | 62.78 (62.81)          | 3.81 (3.88)            | 19.20 (19.27)         |
| 4e    | -4-tert-Butyl| C₂₃H₂₂FN₅O₂ | 175  | 58%     | 65.80 (65.86)          | 5.24 (5.29)            | 16.65 (16.70)         |
| 4f    | -3-NO₂| C₁₉H₁₃FN₆O₄       | 195  | 62%     | 55.85 (55.89)          | 3.16 (3.21)            | 20.50 (20.58)         |
| 4g    | -4-NO₂| C₁₉H₁₃FN₆O₄       | 202  | 65%     | 55.86 (55.89)          | 3.18 (3.21)            | 20.55 (20.58)         |
| 4h    | -4-OH | C₁₉H₁₄FN₅O₃       | 232  | 61%     | 60.11 (60.16)          | 3.69 (3.72)            | 18.40 (18.46)         |
| 4i    | -4-NH₂| C₁₉H₁₅FN₆O₂       | 257  | 53%     | 60.28 (60.31)          | 3.95 (4.00)            | 22.18 (22.21)         |
| 4j    | -2-Cl-4-Cl| C₁₉H₁₂Cl₂FN₅O₂ | 270  | 58%     | 52.75 (52.80)          | 2.76 (2.80)            | 16.15 (16.20)         |

3. 4. N’-(5-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-y1) benzohydrazide (4d):

Mass M⁺ = 363: IR (KBr) v (cm⁻¹), 3436 (-NH, secondary), 2925 (-CH₃, Asym.), 2836 (-CH₃, Sym.), 2217 (-CN), 1636 (-CO), 1092 (N-C), 1625 (-CO, Amide), 1261 (C-O-C), 1251 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 3.41 (s, 3H, N-CH₃), δ 7.06 (1H, Ar-H), δ 7.14 (1H, Ar-H), δ 7.07 (1H, Ar-H), δ 7.14 (1H, Ar-H), δ 7.06 (1H, Ar-H).
3. 5. 4-tert-Butyl-N'-(5-cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl) benzohydrazide (4e):

Mass M⁺ = 419: IR (KBr) v (cm⁻¹), 3431 (-NH, secondary), 2922 (-CH₃, Asym.), 2830 (-CH₃, Sym.), 2221 (-CN), 1646 (-CO), 1089 (N-C), 1621 (-CO, Amide), 1254 (C-O-C), 1248 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 7.30 (s, 3H, N-CH₃), δ 3.38 (s, 3H, N-CH₃), δ 1.34 (9H, CH₃), δ 7.58 (1H, Ar-H), δ 7.56 (1H, Ar-H), δ 7.56 (1H, Ar-H), δ 7.58 (1H, Ar-H).

3. 6. N'-(5-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)-3-nitrobenzohydrazide (4f):

Mass M⁺ = 408: IR (KBr) v (cm⁻¹), 3428 (-NH, secondary), 2928 (-CH₃, Asym.), 2835 (-CH₃, Sym.), 2201 (-CN), 1635 (-CO), 1088 (N-C), 1625 (-CO, Amide), 1253 (C-O-C), 1370 (C-NO₂), 1253 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 7.38 (s, 3H, N-CH₃), δ 7.83 (1H, Ar-H), δ 7.43 (1H, Ar-H), δ 8.17 (1H, Ar-H), δ 8.39 (1H, Ar-H).

3. 7. N'-(5-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)-4-nitrobenzohydrazide (4g):

Mass M⁺ = 408 IR (KBr) v (cm⁻¹), 3430 (-NH, secondary), 2925 (-CH₃, Asym.), 2837 (-CH₃, Sym.), 2206 (-CN), 1638 (-CO), 1091 (N-C), 1627 (-CO, Amide), 1256 (C-O-C), 1360 (C-NO₂), 1248 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 3.37 (s, 3H, N-CH₃), δ 7.29-7.3 (q, 2H, Ar-H), δ 7.80-7.86 (m, 2H, Ar-H).

3. 8. N'-(5-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)-4-hydroxybenzohydrazide (4h):

Mass M⁺ = 379: IR (KBr) v (cm⁻¹), 3430 (-NH, secondary), 2923 (-CH₃, Asym.), 2830 (-CH₃, Sym.), 2210 (-CN), 1640 (-CO), 1093 (N-C), 1630 (-CO, Amide), 1263 (C-O-C), 1400 (O-H), 1242 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 3.39 (s, 3H, N-CH₃), δ 7.32-7.35 (q, 2H, Ar-H), δ 7.81-7.85 (m, 2H, Ar-H).

3. 9. 4-Amino-N'-(5-cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)benzohydrazide (4i):

Mass M⁺ = 378: IR (KBr) v (cm⁻¹), 3432 (-NH, secondary), 2930 (-CH₃, Asym.), 2835 (-CH₃, Sym.), 2209 (-CN), 1640 (-CO), 1092 (N-C), 1612 (-CO, Amide), 1257 (C-O-C), 3400 (N-H, NH₂), 1260 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 3.42 (s, 3H, N-CH₃), δ 7.30-7.32 (q, 2H, Ar-H), δ 7.82-7.84 (m, 2H, Ar-H).

3. 10. 2,4-Dichloro-N'-(5-cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-yl)benzohydrazide (4j):

Mass M⁺ = 331: IR (KBr) v (cm⁻¹), 3430 (-NH, secondary), 2927 (-CH₃, Asym.), 2831 (-CH₃, Sym.), 2205 (-CN), 1640 (-CO), 1088 (N-C), 1607 (-CO, Amide), 1259 (C-O-C), 763 (C-Cl), 1259 (C-F); 1H NMR (δ ppm) (400 MHz, DMSO), δ 3.38 (s, 3H, N-CH₃), δ 7.47 (1H, Ar-H), δ 7.06 (1H, Ar-H), δ 7.41 (1H, Ar-H).
4. CONCLUSION

Rarely reported Aroylhydrazino derivatives of 4-Arylpyrimidine-5-carbonitrile targeted to be prepared by condensing 4-(4-Fluorophenyl)-2-hydrazinyl-1,6-dihydro-1-methyl-6-oxopyrimidine-5-carbonitrile (3) with different aroylchlorides in presence of dry pyridine gave compound N'(5-Cyano-4-(4-fluorophenyl)-1,6-dihydro-1-methyl-6-oxopyrimidin-2-y1)-4-methylbenzohydrazide (4a-j) (Scheme 1) in good yield (Table 1). Result of constitutional characterization of the obtained products by IR, $^1$H-NMR and Mass Spectroscopy showed good agreement with the constitution of the targeted molecules.

Acknowledgement

Authors are thankful to MaharshiDayanand Science College, Porbandar for providing research facilities. We are grateful the NFDD center, Saurashtra University, Rajkot for recording $^1$H NMR, Mass and IR Spectral data.

References

[1] R. K. Bansal, Heterocyclic Chemistry, 5th ed., New age international publishers, (2010) 1.
[2] V. Rao, M. Suresh, Der Pharmacia Letter 2 (2010) 393-402.
[3] K. T. Raut, P. J. Shirote, Der Pharma Chemica 4(4) (2012) 1435-1439.
[4] A. Ghose, V. Viswanadhan, J. Wendoloski, J. Comb. Chem. 1 (1999) 5568.
[5] A. Christian, G. Montalbetti, Tetrahedron 61 (2005) 1082710852.
[6] E. B. Eastwood, A. Bissel, A. M. Hughes, Encriology 38 (1996), 308-314.
[7] A. Kreutzberge, H. Schimmelpfenning, Arch. Pharm., 314 (1981) 34-41.
[8] T. Veda, J. Sakkakibara, J. Nakagami, Chem. Pharm. Bull. 31 (1984) 4263-4269.
[9] R. Kotwa, J. Krepelka, M. Melka, Czech CS 254, 620 (Cl C 07 D 239/47) 15 September 1988, Appl. 86/3, 907, 28 Mar. 1986, 3pp.
[10] K. Atwal, US Patent US 4,769,371 (Cl 514-275, C 07 D 239/42) 6 September 1988, Appl. 45956 01 March 1987, 14pp.
[11] K. Ozeki, T. Ichikawa, T. Hiroyuki, K. Tanimury, M. Sato, H. Yaginuna, Chem. Pharm. Bull. 37 (1989) 1780-1987.
[12] V. Chorine, Compt. Rend. 220 (1945) 150.
[13] Makio Kitazawa, Masuo Akahane, Yashusni Nakano, Chem. Abstr. 112 (1990) 35803.
[14] Y.D. Kulkarni, Ali S, Mohd., S. Rowhani, Indian drugs 25(12) (1988) 505-507.
[15] A. G. Mehta, D. C. Desai, P.B. Desai; J. Inst. Chem., 65(5) (1993), 163-164.
[16] D. R. William; J. Pharm. Sci. 59(12) (1970) 1838.
[17] R. Agrawal, M. K. Shukla, R.K. Satsangi, Indian J. Pharmacol. 14(2) (1982) 177-182.
[18] J. J. Modha et al. Oriental J. Chem. 18(1) (2002) 81-84.
[19] Kambe Satoshi, Saito, Koji, Kishi, Hiroshi Sakurai, Akio, Midorikawa, Hiroshi, Oyama Tech. Coll. Tochigi, Japan 4 (1979) 287-289.

[20] Ram V. J., Arch Pharm (Weinheim, Ger) 323(11) (1990) 895-899.

(Received 12 September 2014; accepted 22 September 2014)